Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema.
Ophthalmologica
; 227(2): 95-9, 2012.
Article
em En
| MEDLINE
| ID: mdl-21893972
ABSTRACT
PURPOSE:
To compare the effects of grid laser (GL), intravitreal bevacizumab (IVB), and intravitreal triamcinolone acetonide (IVTA) in diffuse diabetic macular edema (DDME). PROCEDURES One hundred and twenty-six patients (126 eyes) treated with GL (modified grid), IVTA (4 mg), and IVB (1.25 mg) injections, matched for best corrected visual acuity (BCVA) and OCT-based central macular thickness at presentation, were enrolled. Primary outcome measure was change in best corrected logMAR visual acuity at 1-year follow-up.RESULTS:
Rates of visual stabilization (within ±0.2 logMAR of baseline BCVA) (71.4, 83.3, 78.6%, respectively) were not different between the groups (p = 0.41) at 12-month follow-up. Higher rates of anatomical and functional success, however, were evident in IVB and IVTA groups within 6 months of treatment (p < 0.05 for both). No severe adverse effects except higher intraocular pressure (10 mm Hg from baseline) in one third (14 eyes) of the IVTA cases, who required trabeculectomy in 2 (4.8%) eyes, were observed.CONCLUSIONS:
Intraocular injections may give favorable results within the first 6 months, and after 6 months, GL results seem to be more favorable in the treatment of treatment-naïve, acute, nonischemic, and center-involving DDME.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Triancinolona Acetonida
/
Edema Macular
/
Fotocoagulação a Laser
/
Inibidores da Angiogênese
/
Retinopatia Diabética
/
Anticorpos Monoclonais Humanizados
/
Glucocorticoides
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Humans
/
Middle aged
Idioma:
En
Revista:
Ophthalmologica
Ano de publicação:
2012
Tipo de documento:
Article